美中生物医学与药学专业协会(SABPA)将于本月14日在UCSD举行科技研讨会，今年研讨会的主题是【免疫：疾病治疗科技前沿】（Immunotherapy, the New Frontier of Disease Treatment）. 即日起接受与会者报名。

具体研讨会安排如下：
Date: March 14, 2015 (Saturday) 8:30am To 1:00pm (Breakfast and lunch will be provided)
Location: Institute of Americas, UCSD (directions available at http://www.sabpa.org/web/news_details.php?ID=449)
Registration: https://www.123signup.com/register?id=yppvf
$20 for online registration, $10 for students and post-docs. $40 for on-site registration, Online registration ends March 11, 2015

讨论方向：
Immunotherapy including allergy, diabetes and cancer immunotherapy has been studied for decades, but only recently has it received much attention, especially in oncology area of research. It was the central topic at recent 2014 AACR (American Association for Cancer Research) and ASCO (American Society of Clinical Oncology) annual meetings. With recent FDA approval of immunotherapy agents from Merck and Bristol-Myers for the treatment of cancer, and with much more under development and clinical trials globally, immunotherapy could be the game-changing treatment with its potential to cure certain types of cancer. Many pharmaceutical companies have renewed their strong interests and invested greatly in immunotherapy for multiple disease areas either internally or through external collaborations.

This year’s SABPA Science & Technology Forum XIII will focus on current frontiers in immunotherapy. It will bring academic and industry leaders in the immunotherapy field from San Diego and its neighboring area to address opportunities and challenges of immunotherapy in many disease areas, particularly in cancer.

speakers

8:40 – 9:15

Jonathan Benjamin, M.D.

Medical Director, Amgen
9:15 – 9:45

Greg Daniels, M.D

Medical Oncologist, UCSD Thornton Hospital and UCSD Medical Center
9:45 – 10:15

Michael Cooke, Ph.D.

Director of Immunology, Genomics Institute of the Novartis Research Foundation
10:45 – 11:15

Matthias von Herrath, M.D.

Director of the Center for Type 1 Diabetes Research, La Jolla Institute of Allergy and Immunology
11:15 – 11:45

Jamey Skillings, M.D.

CMO, Tocagen
11:45 – 12:45

Panel Discussion

Lewis R. Vann, Ph.D.

Sr. Manager, In Vivo Pharmacology & Clinical Lab Services, The Jackson Laboratory

Jon Berglin

CEO, Theragene

Jonathan Benjamin, M.D.

Medical Director, Amgen